ZTS
Zoetis Inc. Healthcare - Animal Health Investor Relations →
Zoetis Inc. (ZTS) closed at $78.71 as of 2026-06-19, trading 49.3% below its 200-week moving average of $155.20. This places ZTS in the extreme value zone. The stock is currently moving closer to the line, down from -48.9% last week. With a 14-week RSI of 25, ZTS is in oversold territory.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.82 ratio) is neutral — neither side is clearly dominating.
Over the past 650 weeks of data, ZTS has crossed below its 200-week moving average 6 times. On average, these episodes lasted 22 weeks. Historically, investors who bought ZTS at the start of these episodes saw an average one-year return of +8.7%.
With a market cap of $33.0 billion, ZTS is a large-cap stock. The company generates a free cash flow yield of 5.4%, which is healthy. Return on equity stands at 67.7%, indicating strong profitability. The stock trades at 10.0x book value.
The company has been aggressively buying back shares, reducing its share count by 8.4% over the past three years.
Over the past 12.5 years, a hypothetical investment of $100 in ZTS would have grown to $287, compared to $517 for the S&P 500. ZTS has returned 8.8% annualized vs 14.1% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 3 open-market purchases totaling $886,367. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while ZTS is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been growing at a 19.9% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ZTS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ZTS Crosses Below the Line?
Across 6 historical episodes, buying ZTS when it crossed below its 200-week moving average produced an average return of +2.7% after 12 months (median +13.0%), compared to +19.2% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was +9.2% vs +43.2% for the index.
Each line shows $100 invested at the moment ZTS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices ZTS would reach each dislocation threshold.
Dislocation Price Levels
Prices where ZTS's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-08-04.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $76.86 | Unusually cheap — potential buy zone |
| Value | +1σ | $88.58 | Cheap vs. own history |
| Fair Value | +0σ | $104.51 | Historical mean behavior |
| Expensive | -1σ | $127.44 | Expensive vs. own history |
| Deep Expensive | -2σ | $163.24 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from ZTS's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
ZTS has crossed below its 200-week MA 6 times with an average 1-year return of +8.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jan 2014 | Jun 2014 | 20 | 9.6% | +40.6% | +175.0% |
| Sep 2022 | Jan 2023 | 16 | 12.7% | +18.8% | -45.2% |
| Oct 2023 | Nov 2023 | 2 | 6.6% | +16.5% | -47.8% |
| Mar 2024 | Jul 2024 | 15 | 15.3% | -2.4% | -52.0% |
| Nov 2024 | Dec 2024 | 3 | 0.3% | -30.1% | -54.1% |
| Dec 2024 | Ongoing | 79+ | 52.9% | Ongoing | -51.2% |
| Average | 22 | — | +8.7% | — |
Frequently Asked Questions
Is ZTS below its 200-week moving average?
Yes. As of 2026-06-19, Zoetis Inc. (ZTS) is trading 49.3% below its 200-week moving average of $155.20. The current price is $78.71.
What is ZTS's 200-week moving average price?
Zoetis Inc.'s 200-week moving average is $155.20 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ZTS drops below its 200-week moving average?
ZTS has crossed below its 200-week moving average 6 times in our data. On average, buying at that moment produced a one-year return of +8.7%. These dips have historically been decent entry points. These episodes lasted 22 weeks on average.
Is ZTS a good value right now?
Here's what our data says about ZTS as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 25 (oversold). Free cash flow yield is 5.4%. Return on equity is 67.7%. Price-to-book is 10.0x. This is not a buy or sell recommendation — always do your own research.
How does ZTS compare to the S&P 500?
Over the past 12.5 years, $100 invested in ZTS would have grown to $287, compared to $517 for the S&P 500. That's 8.8% annualized vs 14.1% for the index. ZTS has underperformed the broader market over this period.
Does ZTS pay a dividend?
Yes. Zoetis Inc. currently pays a dividend yield of 267.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19